Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Sarcoma 1Dermatologic 1Breast 1

Conditions

Neoplasms 2Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hemangiosarcoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Interventional × sarilumab × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05704634 2026-04-15

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
56 enrolled
Thoracic

Lung Neoplasms

NCT04333706 2026-03-10

EMPOWER

University of Southern California

Phase 1/2 Recruiting
65 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05428007 2026-01-05

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NYU Langone Health

Phase 2 Recruiting
105 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡